Ninlaro is a type of cancer drug called a proteasome inhibitor which works by blocking enzymes from multiple myeloma cells, hindering their ability to grow.
A Promising Oral Drug Combo for Multiple Myeloma Treatment
In patients with newly diagnosed multiple myeloma, the investigational drug ixazomib when taken orally in combination with lenalidomide and dexamethasone is promising.
In patients with newly diagnosed multiple myeloma, the investigational drug ixazomib when taken orally in combination with lenalidomide and dexamethasone is promising.
‘Multiple Myeloma is a type of a blood cancer affecting the infection-fighting region of plasma cells which then multiply and produce abnormal proteins.’
Study participants received either Ninlaro in combination with lenalidomide and dexamethasone or placebo plus lenalidomide and dexamethasone. The results showed that participants taking the once-weekly regimen lived for an average of 20.6 months compared to 14.7 months in the group receiving a placebo plus Revlimid and dexamethasone, with a tolerable safety profile. ”The introduction of Ninlaro marks an important step forward, as its efficacy and safety profile - coupled with its completely oral administration - potentially can reduce some logistical burdens, and help enable patients to reap the full benefits of this sustainable therapy,” noted Christophe Bianchi, president of Takeda Oncology.
Source-Medindia
Phase III Trial of New Immune Therapy Drug shows Promise Against Multiple Myeloma
The drug, elotuzumab when taken in addition to the standard therapy for multiple myeloma, lowered the death risk or having the cancer return by almost 30%.
The drug, elotuzumab when taken in addition to the standard therapy for multiple myeloma, lowered the death risk or having the cancer return by almost 30%.
Trials to Begin for New Cancer Drug in Multiple Myeloma Patients
A new cancer drug has been developed by scientists at Imperial College London, which they plan to trial in multiple myeloma patients by the end of next year.
A new cancer drug has been developed by scientists at Imperial College London, which they plan to trial in multiple myeloma patients by the end of next year.
Multiple Myeloma / Plasma Cell Myeloma–Symptoms-Treatment-Prognosis-Support Group
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Mehta’s ‘Water’ , declared that she had the incurable Multiple Myeloma.
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Mehta’s ‘Water’ , declared that she had the incurable Multiple Myeloma.
